Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
about
Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipientsPosttransplant lymphoproliferative disorders following liver transplantation: Where are we now?Neoplastic disease after liver transplantation: Focus on de novo neoplasmsSkin cancer in organ transplant recipients: effects of immunosuppressive medications on DNA repairEmerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorderBurden of de novo malignancy in the liver transplant recipientRapalogs in cancer prevention: anti-aging or anticancer?Lifespan extension and cancer prevention in HER-2/neu transgenic mice treated with low intermittent doses of rapamycinGenetic polymorphisms of mTOR and cancer risk: a systematic review and updated meta-analysisHPV-related cancers after solid organ transplantation in the United StatesTopical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Sirolimus in pediatric renal transplantation.Validation of anti-aging drugs by treating age-related diseases.Invasive squamous cell bladder cancer of the ureterovesical junction in a renal transplant patient: a case report.Donor transmitted and de novo cancer after liver transplantation.Distinct innate immune gene expression profiles in non-melanoma skin cancer of immunocompetent and immunosuppressed patientsDouble umbilical cord blood transplantation with reduced intensity conditioning and sirolimus-based GVHD prophylaxis.Calcineurin inhibitors and rapamycin: cancer protection or promotion?Anorectal human papillomavirus: current conceptsImmune profiling and cancer post transplantationRoles of the immune system in skin cancer.Renal transplantation, immunosuppression and the skin: an update.Tumor suppression by p53 without apoptosis and senescence: conundrum or rapalog-like gerosuppression?Skin cancer as a contraindication to organ transplantation.Rejuvenating immunity: "anti-aging drug today" eight years later.How to save Medicare: the anti-aging remedy.Sirolimus: its role in nephrology.Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey.Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/- micePost-transplant de novo malignancies in renal transplant recipients: the past and present.Hedgehog signalling in skin development and cancer.Conversion to sirolimus in kidney transplant recipients with squamous cell cancer and changes in immune phenotypeThe role and value of sirolimus administration in kidney and liver transplantation.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Immunosuppression and tumor development in organ transplant recipients: the emerging dualistic role of rapamycin.Transient rapamycin treatment can increase lifespan and healthspan in middle-aged mice.Epstein-Barr virus, rapamycin, and host immune responses.Considerations in sirolimus use in the early and late post-transplant periods.The rationale for mTOR inhibition in epithelial ovarian cancer.
P2860
Q24246340-099C6D53-B12A-43DD-B946-24B13515EF95Q26780262-2C30A66A-AD23-4B9B-B072-5ADC984F3378Q26798306-8E7FB0CC-323C-4A1C-9B7B-5BA6F9B40ECBQ26822549-0AA1C957-5078-4717-BB4B-2384BEF0E29CQ26859114-A8EF9C30-339F-4104-A61F-70CF5B75D4CDQ26859216-2BB6FF9E-4B6E-4673-A532-296BDA20A9BDQ26866151-6E5A95D8-07D3-4ABC-AB2D-CD4DA3113BE1Q28307873-F90A576B-4798-41BB-BC9B-963566BF374AQ29248629-7DF1FC10-F76A-4256-92F5-5BF1C2E73C3AQ30580161-327B4552-8766-441D-9FEB-7CF805F16D53Q33316872-3543D632-C599-4B1C-82E5-B59993BFB7F5Q33346685-91CA49CE-A663-48BF-9F77-6217CFD77045Q33397668-BA2E80A9-DCD0-4915-8F0F-4BB9F74BC756Q33588700-D2AD8C1C-AA09-402A-811E-7DDAA97F27C4Q33622472-6AF85EC4-6AFD-4151-9CB0-A43CD110BEDDQ33661124-D7203AA9-0FFA-4475-8D29-E6BD0C274DEAQ34342371-7635BBA2-5757-457C-AE02-F6BB162125C9Q34451427-7191B191-D30B-453C-A3CB-DEB4360784E9Q34578721-B400C9ED-B771-48A4-931D-14C68DC77407Q34637540-8C543A85-9386-4267-97D3-CAD74538DB38Q35050810-74121C6F-6F37-4A45-8F7A-EABB6699AF8CQ35403714-14BE9636-5573-48F0-A3C5-A8DE33ABDF4BQ36000874-61CE3191-9991-46A8-A51A-DC56AA5C8E52Q36209128-988BEDED-6319-4BE1-BE0E-AEC545D4B7D8Q36226526-1EAD4176-561E-43F4-982C-6FD4B86F29A5Q36260537-5333F50C-2596-4BB1-BB04-A2A5308D2C17Q36288653-C28934F7-9EC7-4377-8575-6B0E3D35CEEEQ36341793-0E4E34AC-3546-4815-8EA5-A42DCEBC2EDBQ36381533-99CB9E5D-7D11-4069-A170-1E57EF6E9520Q36455201-73ECB583-C851-4DA2-84A4-8804B883280EQ36530274-3F4391F5-5AB1-44E5-A115-57E4AB799B9DQ36553688-3C6D63BE-8343-4442-B9BC-A98497749567Q36610844-061B5376-D410-4530-A12A-DAE5113B47BCQ36652031-BF3D55CA-1FDD-4A39-AEE7-96D91367E576Q36884566-216E09CB-456E-4814-BEFA-D1EA3C472275Q37028215-9F8B4271-C4A0-4AA5-9F99-76AFEB887C54Q37201250-690B4935-96A8-4D06-AAD5-57D389FB3CF1Q37342546-23F899CA-197D-40FE-B540-66BD33080DA0Q37517602-AB945A76-5752-46D6-B975-680FEE11788FQ37627253-57D2D84E-32BE-487B-A527-7E63DF841626
P2860
Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Two-year incidence of malignan ...... from five multicenter studies.
@en
Two-year incidence of malignan ...... from five multicenter studies.
@nl
type
label
Two-year incidence of malignan ...... from five multicenter studies.
@en
Two-year incidence of malignan ...... from five multicenter studies.
@nl
prefLabel
Two-year incidence of malignan ...... from five multicenter studies.
@en
Two-year incidence of malignan ...... from five multicenter studies.
@nl
P2093
P2860
P1476
Two-year incidence of malignan ...... from five multicenter studies.
@en
P2093
Henri Kreis
Peter Friend
Timothy Mathew
P2860
P304
P356
10.1111/J.1399-0012.2004.00188.X
P577
2004-08-01T00:00:00Z